These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 26209382)

  • 1. The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection.
    Garbuglia AR; Lionetti R; Lapa D; Taibi C; Visco-Comandini U; Montalbano M; D'Offizi G; Castiglione F; Capobianchi MR; Paci P
    J Clin Virol; 2015 Aug; 69():68-73. PubMed ID: 26209382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early decline of the HCV core antigen can predict SVR in patients with HCV treated by Pegylated interferon plus ribavirin combination therapy.
    Fujino T; Nakamuta M; Aoyagi Y; Fukuizumi K; Takemoto R; Yoshimoto T; Miyahara T; Harada N; Sakai H; Nakashima M; Enjoji M
    J Dig Dis; 2009 Feb; 10(1):21-5. PubMed ID: 19236543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection.
    Vermehren J; Susser S; Berger A; Perner D; Peiffer KH; Allwinn R; Zeuzem S; Sarrazin C
    J Clin Virol; 2012 Sep; 55(1):17-22. PubMed ID: 22698697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of a new immunoradiometric assay of HCV core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral load of serum HCV RNA genotype 1b.
    Sasase N; Kim SR; Kim KI; Taniguchi M; Imoto S; Mita K; Hotta H; Shouji I; El-Shamy A; Kawada N; Kudo M; Hayashi Y
    Intervirology; 2008; 51 Suppl 1():70-5. PubMed ID: 18544951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy.
    Takahashi M; Saito H; Higashimoto M; Atsukawa K; Ishii H
    J Clin Microbiol; 2005 Jan; 43(1):186-91. PubMed ID: 15634970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1.
    Bárcena R; Moreno A; del Campo S; Muriel A; Mateos ML; Garrido E; García M; Quereda C; Moreno S; Moreno A
    Antivir Ther; 2007; 12(3):401-6. PubMed ID: 17591030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrasensitive HCV RNA Quantification in Antiviral Triple Therapy: New Insight on Viral Clearance Dynamics and Treatment Outcome Predictors.
    Garbuglia AR; Visco-Comandini U; Lionetti R; Lapa D; Castiglione F; D'Offizi G; Taibi C; Montalbano M; Capobianchi MR; Paci P
    PLoS One; 2016; 11(8):e0158989. PubMed ID: 27560794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection.
    Ogawa E; Furusyo N; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Nakamuta M; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    Antiviral Res; 2014 Apr; 104():102-9. PubMed ID: 24462955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: a comparison of two real-time PCR assays.
    Ogawa E; Furusyo N; Murata M; Toyoda K; Eiraku K; Shimizu M; Harada Y; Mitsumoto F; Takayama K; Okada K; Kainuma M; Hayashi J
    Antiviral Res; 2013 Aug; 99(2):119-24. PubMed ID: 23684903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection.
    Feng B; Yang RF; Xie Q; Shang J; Kong FY; Zhang HY; Rao HY; Jin Q; Cong X; Liu YY; Kang Y; Wei L
    BMC Gastroenterol; 2014 Mar; 14():47. PubMed ID: 24625322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome.
    Cento V; Di Paolo D; Di Carlo D; Micheli V; Tontodonati M; De Leonardis F; Aragri M; Antonucci FP; Di Maio VC; Mancon A; Lenci I; Manunta A; Taliani G; Di Biagio A; Nicolini LA; Nosotti L; Sarrecchia C; Siciliano M; Landonio S; Pellicelli A; Gasbarrini A; Vecchiet J; Magni CF; Babudieri S; Mura MS; Andreoni M; Parruti G; Rizzardini G; Angelico M; Perno CF; Ceccherini-Silberstein F
    Dig Liver Dis; 2015 Feb; 47(2):157-63. PubMed ID: 25544656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1.
    Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2012 Jul; 84(7):1097-105. PubMed ID: 22585728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C Virus Core Antigen (HCVAg): an affordable assay to monitor the efficacy of treatment in DAAs era.
    Rossetti B; Loggi E; Raffaelli CS; Mercinelli S; Gandolfo C; Savellini GG; Galli S; Vitale G; Di Donato R; Vukotic R; Grandini E; Margotti M; Guarneri V; Furlini G; Re MC; De Luca A; Andreone P; Galli C; Cusi MG
    New Microbiol; 2021 Apr; 44(2):89-94. PubMed ID: 34151994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
    Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
    J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.
    Lunel F; Veillon P; Fouchard-Hubert I; Loustaud-Ratti V; Abergel A; Silvain C; Rifflet H; Blanchi A; Causse X; Bacq Y; Payan C;
    J Hepatol; 2003 Nov; 39(5):826-33. PubMed ID: 14568267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings.
    Butt AA; Yan P; Shaikh OS; Freiberg MS; Lo Re V; Justice AC; Sherman KE;
    J Viral Hepat; 2015 Sep; 22(9):691-700. PubMed ID: 25524834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes.
    Garbuglia AR; Monachetti A; Galli C; Sabatini R; Ferreri ML; Capobianchi MR; Bagnarelli P
    BMC Infect Dis; 2014 Apr; 14():222. PubMed ID: 24758157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus free-virion and immune-complex dynamics during interferon therapy with and without ribavirin in genotype-1b chronic hepatitis C patients.
    Fujita N; Kaito M; Tanaka H; Horiike S; Urawa N; Sugimoto R; Konishi M; Watanabe S; Adachi Y
    J Viral Hepat; 2006 Mar; 13(3):190-8. PubMed ID: 16475995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.